Pluri

Its PLX-R18 is a placenta-derived cell therapy intended to regenerate bone marrow and blood cells after acute radiation exposure. The US Food and Drug Administration cleared an investigational new drug application for acute radiation syndrome and granted orphan drug designation, but PLX-R18 is not approved.

The US National Institute of Allergy and Infectious Diseases awarded a 4.2 million dollar development contract that was terminated effective 15 April 2025, and the company reported receiving 2.3 million dollars under it, according to its 10-K and an 8-K filed in April 2025. Pluri's other programmes address non-radiological indications, so the radiological letter applies only to PLX-R18.

Publicly listed on Nasdaq (PLUR); incorporated in Nevada on 11 May 2001

Parent: none (publicly listed) (checked)

• https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/ea0304639-10k_pluri.htm
• https://pluri-biotech.com/clinical-pipeline/
• https://pluri-biotech.com/plxr18-ars/
• https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=626418
• https://www.sec.gov/Archives/edgar/data/1158780/000121390025032948/ea0238672-8k_pluri.htm

• Whether any later non-dilutive funding for the radiation programme exists: not found.
• The company was founded earlier under a different name: not checked.